1
|
Kim JH, Hong JH, Jung JG, Jung WT, Nam KY, Roh JS, Choi YW, Bang J, Huh H, Lee HJ, Moon J, Kim J, Sunwoo J. Pharmacokinetic and Safety Comparison of Fixed-Dose Combination of Cilostazol/Rosuvastatin (200 + 20 mg) Versus Concurrent Administration of the Separate Components in Healthy Adults. Clin Pharmacol Drug Dev 2024; 13:842-851. [PMID: 38469999 DOI: 10.1002/cpdd.1390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Accepted: 01/23/2024] [Indexed: 03/13/2024]
Abstract
The combined cilostazol and rosuvastatin therapy is frequently used for coronary artery disease treatment. This open-label, 3 × 3 crossover clinical trial evaluated the pharmacokinetics and safety of a fixed-dose combination (FDC) of cilostazol/rosuvastatin (200 + 20 mg) versus a concurrent administration of the separate components (SCs) under both fasted and fed conditions. Among 48 enrolled healthy adults, 38 completed the study. Participants were administered a single oral dose of cilostazol/rosuvastatin (200 + 20 mg), either as an FDC or SCs in a fasted state, or FDC in a fed state, in each period of the trial. Blood samples were taken up to 48 hours after dosing, and plasma concentrations were analyzed using validated liquid chromatography-tandem mass spectrometry. The geometric mean ratios of FDC to SCs for area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUClast) and maximum plasma concentration (Cmax) were 0.94/1.05 and 1.06/1.15 for cilostazol and rosuvastatin, respectively (AUClast/Cmax). Compared with that during fasting, fed-state administration increased the AUClast and Cmax for cilostazol by approximately 72% and 160% and decreased these parameters for rosuvastatin by approximately 39% and 43%, respectively. To conclude, the FDC is bioequivalent to the SCs, with notable differences in pharmacokinetics when administered in a fed state. No significant safety differences were observed between the treatments.
Collapse
Affiliation(s)
- Jae Hoon Kim
- Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea
- Department of Medical Science, Chungnam National University College of Medicine, Daejeon, Republic of Korea
| | - Jang Hee Hong
- Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea
- Department of Pharmacology, Chungnam National University College of Medicine, Daejeon, Republic of Korea
| | - Jin-Gyu Jung
- Department of Family Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea
| | - Won Tae Jung
- Korea United Pharmaceutical Corporation, Seoul, Republic of Korea
| | - Kyu-Yeol Nam
- Korea United Pharmaceutical Corporation, Seoul, Republic of Korea
| | - Jae Seok Roh
- Korea United Pharmaceutical Corporation, Seoul, Republic of Korea
| | - Youn Woong Choi
- Korea United Pharmaceutical Corporation, Seoul, Republic of Korea
| | - Junbae Bang
- Korea United Pharmaceutical Corporation, Seoul, Republic of Korea
| | - Hyunwook Huh
- Korea United Pharmaceutical Corporation, Seoul, Republic of Korea
| | - Hye J Lee
- Caleb Multilab Corporation, Seoul, Republic of Korea
| | - JungHa Moon
- Caleb Multilab Corporation, Seoul, Republic of Korea
| | - Jaehee Kim
- Caleb Multilab Corporation, Seoul, Republic of Korea
| | - Jung Sunwoo
- Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea
| |
Collapse
|
2
|
Tsume Y. Evaluation and prediction of oral drug absorption and bioequivalence with food-drug interaction. Drug Metab Pharmacokinet 2023; 50:100502. [PMID: 37001300 DOI: 10.1016/j.dmpk.2023.100502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Revised: 02/21/2023] [Accepted: 03/02/2023] [Indexed: 03/08/2023]
Abstract
This article reviews the impacts on the in vivo prediction of oral bioavailability (BA) and bioequivalence (BE) based on Biopharmaceutical classification systems (BCS) by the food-drug interaction (food effect) and the gastrointestinal (GI) environmental change. Various in vitro and in silico predictive methodologies have been used to expect the BA and BE of the test oral formulation. Food intake changes the GI physiology and environment, which affect oral drug absorption and its BE evaluation. Even though the pHs and bile acids in the GI tract would have significant influence on drug dissolution and, hence, oral drug absorption, those impacts largely depend on the physicochemical properties of oral medicine, active pharmaceutical ingredients (APIs). BCS class I and III drugs are high soluble drugs in the physiological pH range, food-drug interaction may not affect their BA. On the other hand, BCS class II and IV drugs have pH-dependent solubility, and the more bile acid secretion and the pH changes by food intake might affect their BA. In this report, the GI physiological changes between the fasted and fed states are described and the prediction on the oral drug absorption by food-drug interaction have been introduced.
Collapse
|
3
|
Zhu KW, Wang GM, Li CY, Liu JY, Huang JY, Wu JR, Song WJ, Deng J, Wang JS, Qin F. Pharmacokinetics and Bioequivalence of Two Formulations of Rosuvastatin Following Single-dose Administration in Healthy Chinese Subjects Under Fasted and Fed Conditions. Clin Pharmacol Drug Dev 2022; 11:987-996. [PMID: 35567420 DOI: 10.1002/cpdd.1112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2021] [Accepted: 04/25/2022] [Indexed: 11/06/2022]
Abstract
The main objective of the study was to evaluate the bioequivalence of two rosuvastatin calcium tablets in healthy Chinese subjects under fasted and fed conditions. The study was carried out using a randomized, open-label, two-formulation, two-sequence, two-period, single-dose crossover design, with a washout period of 7 days. Both the fasted study and fed study enrolled 28 subjects. In each study period, the subjects were administrated a single oral dose of the test product or reference product of rosuvastatin 10 mg. Blood samples were collected from pre-dose to 72 hours after administration with 16 time points in total. Bioequivalence evaluation was performed using ln-transformed pharmacokinetic parameters of rosuvastatin, including Cmax , AUC0-t , and AUC0-∞ . In the present study, 95% confidence intervals (CIs) of test/reference geometric mean ratios (GMRs) of Cmax , AUC0-t , and AUC0-∞ under the fasted and fed conditions were all within the acceptance range of 80%-125%. Additionally, only one subject experienced one adverse event (AE). High-fat meals reduced the Cmax , AUC0-t , and AUC0-∞ , but had no significant effects on the λz, t1/2 , or Tmax of rosuvastatin. In the current study, the test product was bioequivalent to the reference product, and a single dose of rosuvastatin (10 mg) was well-tolerated. Food decreased the systemic exposure of rosuvastatin without the effects on the Tmax or elimination rate.
Collapse
Affiliation(s)
- Ke-Wei Zhu
- Department of Clinical Research, Institute of Pharmacology, GuangZhou BaiYunShan Pharmaceutical Holdings CO., LTD. BaiYunShan Pharmaceutical General Factory, Guangzhou, China.,Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province, Department of Science and Technology of Guangdong Province, People's Government of Guangdong Province, Guangzhou, China
| | - Gan-Mi Wang
- Department of Clinical Research, Institute of Pharmacology, GuangZhou BaiYunShan Pharmaceutical Holdings CO., LTD. BaiYunShan Pharmaceutical General Factory, Guangzhou, China.,Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province, Department of Science and Technology of Guangdong Province, People's Government of Guangdong Province, Guangzhou, China
| | - Chu-Yuan Li
- Office of Company Leadership, Corporate Headquarters, Guangzhou Pharmaceutical Holdings Limited, Guangzhou, China
| | - Ju-Yan Liu
- Office of Company Leadership, Corporate Headquarters, Guangzhou Pharmaceutical Holdings Limited, Guangzhou, China
| | - Jin-Ying Huang
- Department of Clinical Research, Institute of Pharmacology, GuangZhou BaiYunShan Pharmaceutical Holdings CO., LTD. BaiYunShan Pharmaceutical General Factory, Guangzhou, China.,Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province, Department of Science and Technology of Guangdong Province, People's Government of Guangdong Province, Guangzhou, China.,Phase Ⅰ Clinical Research Center, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
| | - Jia-Rong Wu
- Department of Clinical Research, Institute of Pharmacology, GuangZhou BaiYunShan Pharmaceutical Holdings CO., LTD. BaiYunShan Pharmaceutical General Factory, Guangzhou, China.,Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province, Department of Science and Technology of Guangdong Province, People's Government of Guangdong Province, Guangzhou, China.,Phase Ⅰ Clinical Research Center, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
| | - Wen-Jie Song
- Department of Clinical Research, Institute of Pharmacology, GuangZhou BaiYunShan Pharmaceutical Holdings CO., LTD. BaiYunShan Pharmaceutical General Factory, Guangzhou, China.,Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province, Department of Science and Technology of Guangdong Province, People's Government of Guangdong Province, Guangzhou, China.,Phase Ⅰ Clinical Research Center, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
| | - Jun Deng
- Department of Clinical Research, Institute of Pharmacology, GuangZhou BaiYunShan Pharmaceutical Holdings CO., LTD. BaiYunShan Pharmaceutical General Factory, Guangzhou, China.,Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province, Department of Science and Technology of Guangdong Province, People's Government of Guangdong Province, Guangzhou, China.,Phase Ⅰ Clinical Research Center, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
| | - Jian-Song Wang
- Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province, Department of Science and Technology of Guangdong Province, People's Government of Guangdong Province, Guangzhou, China.,Office of Factory Director, GuangZhou BaiYunShan Pharmaceutical Holdings CO., LTD. BaiYunShan Pharmaceutical General Factory, Guangzhou, China
| | - Fei Qin
- Department of Clinical Research, Institute of Pharmacology, GuangZhou BaiYunShan Pharmaceutical Holdings CO., LTD. BaiYunShan Pharmaceutical General Factory, Guangzhou, China.,Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province, Department of Science and Technology of Guangdong Province, People's Government of Guangdong Province, Guangzhou, China
| |
Collapse
|
4
|
Sun Q, Li L, Zhou Q. Effects of Ethanolic Extract of Schisandra sphenanthera on the Pharmacokinetics of Rosuvastatin in Rats. Drug Des Devel Ther 2022; 16:1473-1481. [PMID: 35607596 PMCID: PMC9123906 DOI: 10.2147/dddt.s364234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2022] [Accepted: 05/10/2022] [Indexed: 11/23/2022] Open
Abstract
Purpose Wuzhi capsule (WZ) is a proprietary Chinese medicine prepared from the ethanolic extract of Schisandra sphenanthera that is commonly used to treat liver injury. Statins are widely used in patients with hyperlipidemia, coronary heart disease, metabolic syndrome, type 2 diabetes mellitus, and nonalcoholic fatty liver disease. Co-administration of statins with WZ is possible in clinical practice. WZ has obvious inhibitory effects on the bioavailability of atorvastatin and simvastatin; however, the drug–herb interactions between WZ and rosuvastatin have not been addressed. We explored the effects of WZ on the pharmacokinetics of rosuvastatin in Sprague-Dawley rats to promote a rational use of statins. Methods Eighteen male rats were randomly and evenly divided into three groups: control group (gavage feeding of rosuvastatin 10 mg·kg−1), single dose group (gavage feeding of a single dose of WZ 150 mg·kg−1 followed by rosuvastatin 10 mg·kg−1) and multiple doses group (gavage feeding of WZ 150 mg·kg−1 for 7 days followed by rosuvastatin 10 mg·kg−1 on the seventh day). Plasma samples were collected at different times before and after rosuvastatin administration. The other 18 female rats were tested the same way as the male rats. All samples were analyzed by a validated LC-MS/MS method, and the pharmacokinetic parameters were calculated using a non-compartmental model. Results In both male and female rats, there were no statistically significant differences in rosuvastatin pharmacokinetic parameters between the control group, the single dose group, and the multi-dose group. Conclusion Acute or long-term intake of WZ had no obvious effect on the pharmacokinetics of rosuvastatin, and therefore rosuvastatin could be used as an alternative to atorvastatin and simvastatin when WZ is clinically required in conjunction with statins. An appropriate pharmacodynamic study is needed to encourage the safe use of this combination.
Collapse
Affiliation(s)
- Qing Sun
- Department of Pharmacy, Zhejiang Hospital, Hangzhou, People’s Republic of China
| | - Li Li
- Department of Pharmacy, Zhejiang Hospital, Hangzhou, People’s Republic of China
- Li Li, Department of Pharmacy, Zhejiang Hospital, No. 12 Lingyin Road, Hangzhou, 310013, Zhejiang Province, People’s Republic of China, Email
| | - Quan Zhou
- Department of Pharmacy, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
- Correspondence: Quan Zhou, Department of Pharmacy, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Jiefang Road No. 88, Shangcheng District, Hangzhou, 310009, Zhejiang Province, People’s Republic of China, Tel +86 571 89713473, Email
| |
Collapse
|
5
|
Silveira AMR, Duarte GHB, Fernandes AMADP, Garcia PHD, Vieira NR, Antonio MA, Carvalho PDO. Serum Predose Metabolic Profiling for Prediction of Rosuvastatin Pharmacokinetic Parameters in Healthy Volunteers. Front Pharmacol 2021; 12:752960. [PMID: 34867363 PMCID: PMC8633954 DOI: 10.3389/fphar.2021.752960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2021] [Accepted: 10/13/2021] [Indexed: 11/23/2022] Open
Abstract
Rosuvastatin is a well-known lipid-lowering agent generally used for hypercholesterolemia treatment and coronary artery disease prevention. There is a substantial inter-individual variability in the absorption of statins usually caused by genetic polymorphisms leading to a variation in the corresponding pharmacokinetic parameters, which may affect drug therapy safety and efficacy. Therefore, the investigation of metabolic markers associated with rosuvastatin inter-individual variability is exceedingly relevant for drug therapy optimization and minimizing side effects. This work describes the application of pharmacometabolomic strategies using liquid chromatography coupled to mass spectrometry to investigate endogenous plasma metabolites capable of predicting pharmacokinetic parameters in predose samples. First, a targeted method for the determination of plasma concentration levels of rosuvastatin was validated and applied to obtain the pharmacokinetic parameters from 40 enrolled individuals; then, predose samples were analyzed using a metabolomic approach to search for associations between endogenous metabolites and the corresponding pharmacokinetic parameters. Data processing using machine learning revealed some candidates including sterols and bile acids, carboxylated metabolites, and lipids, suggesting the approach herein described as promising for personalized drug therapy.
Collapse
Affiliation(s)
| | | | | | | | - Nelson Rogerio Vieira
- Integrated Unit of Pharmacology and Gastroenterology (UNIFAG), São Francisco University-USF, Bragança Paulista, Brazil
| | - Marcia Aparecida Antonio
- Integrated Unit of Pharmacology and Gastroenterology (UNIFAG), São Francisco University-USF, Bragança Paulista, Brazil
| | | |
Collapse
|
6
|
Effect of Genetic Polymorphisms on the Pharmacokinetics of Deferasirox in Healthy Chinese Subjects and an Artificial Neural Networks Model for Pharmacokinetic Prediction. Eur J Drug Metab Pharmacokinet 2020; 45:761-770. [PMID: 32930952 DOI: 10.1007/s13318-020-00647-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND AND OBJECTIVE Deferasirox is an oral iron chelator used to reduce iron levels in iron-overloaded patients with transfusion-dependent anemia or non-transfusion-dependent thalassemia. This study investigated the effects of genetic polymorphisms on the pharmacokinetics of deferasirox in healthy Chinese subjects and constructed a pharmacokinetic prediction model based on physiologic factors and genetic polymorphism data. METHODS Twenty-eight subjects were enrolled in a randomized, open-label, two-period crossover study, and they received a single dose of one of two formulations of deferasirox (20 mg/kg) with a 7-day washout interval between the two periods. The plasma defersirox concentration was determined using a validated liquid chromatography-tandem mass spectrometry method, and pharmacokinetic parameters were calculated using the noncompartmental method. The polymorphisms of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), UGT1A3, multidrug resistance protein 2 (MRP2), cytochrome P450 1A1 (CYP1A1), and breast cancer resistance protein 1 (BCRP1) were genotyped using Sanger sequencing. A back-propagation artificial neural network (BP-ANN) model was used to predict the pharmacokinetics. RESULTS The UGT1A1 rs887829 C > T single-nucleotide polymorphism (SNP) significantly influenced the area under the plasma concentration-time curve and the terminal half-life. Neither the MRP2 rs2273697 G > A SNP nor BCRP1 rs2231142 G > T SNP altered the absorption, disposition, and excretion of the drug. The BP-ANN model had a high goodness-of-fit index and good coherence between the predicted and measured concentrations (R2 = 0.921). CONCLUSION Metabolic enzyme-related genetic polymorphisms were more strongly associated with the pharmacokinetics of deferasirox than membrane transporter-related genetic polymorphisms in the Chinese population. TRIAL REGISTRATION www.Chinadrugtrials.org.cn CTR20191164.
Collapse
|
7
|
Xu Y, Lou H, Chen J, Jiang B, Yang D, Hu Y, Ruan Z. Application of a Backpropagation Artificial Neural Network in Predicting Plasma Concentration and Pharmacokinetic Parameters of Oral Single‐Dose Rosuvastatin in Healthy Subjects. Clin Pharmacol Drug Dev 2020; 9:867-875. [PMID: 32452647 DOI: 10.1002/cpdd.809] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2019] [Accepted: 04/06/2020] [Indexed: 11/08/2022]
Affiliation(s)
- Yichao Xu
- Center of Clinical Pharmacology Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang China
| | - Honggang Lou
- Center of Clinical Pharmacology Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang China
| | - Jinliang Chen
- Center of Clinical Pharmacology Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang China
| | - Bo Jiang
- Center of Clinical Pharmacology Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang China
| | - Dandan Yang
- Center of Clinical Pharmacology Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang China
| | - Yin Hu
- Center of Clinical Pharmacology Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang China
| | - Zourong Ruan
- Center of Clinical Pharmacology Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang China
| |
Collapse
|
8
|
Du P, Li P, Liu H, Zhao R, Zhao Z, Yu W, Zhou X, Liu L. Open-Label, Randomized, Single-Dose, 2-Period, 2-Sequence Crossover, Comparative Pharmacokinetic Study to Evaluate Bioequivalence of 2 Oral Formulations of Olanzapine Under Fasting and Fed Conditions. Clin Pharmacol Drug Dev 2019; 9:621-628. [PMID: 31595704 DOI: 10.1002/cpdd.743] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2019] [Accepted: 09/08/2019] [Indexed: 11/09/2022]
Abstract
Olanzapine, a second-generation atypical antipsychotic drug, is widely used for schizophrenia and moderate to severe mania associated with bipolar disorders. This open-label, randomized, single-dose, 2-sequence, 2-period crossover, comparative pharmacokinetic study assessed the bioequivalence of 5 mg of olanzapine administered in tablet (R) or disintegrating tablet (T) formulation in healthy Chinese volunteers under both fasting and fed conditions. Numbers of enrolled subjects were 30 and 24 for fasting and fed treatments, respectively. Blood samples were drawn and collected predose as well as up to 144 hours postdose. The plasma concentration of olanzapine was quantitated by a robust, rapid, and sensitive liquid chromatography-tandem mass spectrometry method. The R was bioequivalent to T formulation under either fasting or fed conditions. The 90%CI for ratios of the geometric means observed maximum plasma concentration, area under the curve from time 0 extrapolated to last time point, and area under the curve from time 0 extrapolated to infinity were all within the allowed limit (80.0% to 125.0%). The pharmacokinetic profiles of T and R formulations were similar under fasting and fed conditions. Both formulations were well tolerated, with a similar incidence of treatment-emergent adverse events under fasting and fed conditions.
Collapse
Affiliation(s)
- Ping Du
- Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China
| | - Pengfei Li
- Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China
| | - Hongchuan Liu
- Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China
| | - Rui Zhao
- Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China
| | - Zhixia Zhao
- Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China
| | - Weiyue Yu
- Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China
| | - Xin Zhou
- Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China
| | - Lihong Liu
- Phase I Clinical Trial Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China
| |
Collapse
|
9
|
Nishida C, Matsumoto Y, Fujimoto K, Shirakawa M, Wrishko RE, Behm MO, Furihata K. The Bioequivalence and Effect of Food on the Pharmacokinetics of a Fixed-Dose Combination Tablet Containing Rosuvastatin and Ezetimibe in Healthy Japanese Subjects. Clin Transl Sci 2019; 12:704-712. [PMID: 31365188 PMCID: PMC6853265 DOI: 10.1111/cts.12677] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2019] [Accepted: 06/21/2019] [Indexed: 11/29/2022] Open
Abstract
Certain patient populations are unable to achieve the recommended low‐density lipoprotein cholesterol goals with statin monotherapy alone. Such patients may benefit from concomitant therapy with ezetimibe (EZE) 10 mg added on to a statin. To this end, fixed‐dose combination (FDC) tablets containing EZE 10 mg and rosuvastatin (ROS) 2.5 mg (EZE/ROS2.5) and EZE 10 mg and ROS 5 mg (EZE/ROS5) have been developed for treatment of hypercholesterolemia. The purpose of the series of clinical studies reported herein was to evaluate the potential food effect (MK‐0653H, protocol 836 (P836)) and the bioequivalence between FDC and co‐administration of EZE and ROS in healthy Japanese subjects under fasted and fed conditions (MK‐0653H, protocol 835 (P835) and MK‐0653H, protocol 846 (P846), respectively). These studies show there is no clinically relevant food effect on EZE exposure following single oral administration of the FDC EZE/ROS5 in healthy Japanese subjects; however, ROS exposure was decreased in the fed state under conditions used to evaluate the maximum food effect. Following single oral administration of individual ROS tablets under the same conditions, the magnitude of decrease in ROS exposure was comparable to that seen with FDC, suggesting that the effect of food on ROS exposure was similar between the FDC tablet and co‐administration of individual EZE and ROS tablets. The FDC EZE/ROS5 was generally well tolerated in healthy Japanese subjects under fasted and fed conditions.
Collapse
|